Ojjaara (momelotinib) approved by FDA to treat intermediate or high-risk myelofibrosis – GSK
GSK plc announced that the FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential… read more.
